Cosmos Health Inc. (NASDAQ: 
COSM) is on our radar as price action begins to signal a potential upside reversal, with the stock now setting up for a move that could challenge the $1 resistance zone if momentum continues to build. After a prolonged correction, COSM is showing early technical signs that downside pressure is fading and buyers are starting to step back in.
Cosmos Health operates as a diversified pharmaceutical and healthcare company with an international footprint spanning Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus, while being headquartered in Chicago. The company manufactures and distributes prescription medications, over-the-counter drugs, nutraceuticals, medical devices, cosmetics, and wellness products across multiple established brands, including Sky Premium Life and Mediterranation.
From a market standpoint, COSM shares are down approximately 36.9% over the past 52 weeks, a decline that has pushed the stock into oversold territory and reset expectations. The recent consolidation appears constructive rather than weak, with selling pressure easing as price stabilizes.
Technically, COSM is trading within a well-defined falling wedge pattern, a structure commonly associated with bullish reversals following extended downtrends. The RSI remains near 42, suggesting the stock is no longer overbought and that downside momentum has largely been exhausted. As price continues to compress toward the upper boundary of the wedge, the probability of a breakout is increasing.
A confirmed move above the wedge resistance would open the door for a broader trend shift, placing the $2 level back into focus as a key upside area traders will be watching. This technical setup, combined with the stock’s discounted valuation and diversified healthcare exposure, is why Cosmos Health stands out as our new pick at current levels.
January 20, 2026: Press Release
Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue
Greg Siokas, CEO of Cosmos Health, stated:
"Cosmofarm continues its record-setting momentum, reflecting strong execution across customer acquisition, improving unit economics, and operational efficiency. Our ongoing investment in advanced automation significantly expands capacity and positions the platform to support incremental annual revenue potential of approximately $40 million as volumes scale. As we expand robotic infrastructure and last-mile capabilities, Cosmofarm remains a strategically important asset supporting sustainable growth and long-term value creation for Cosmos Health.”
COSM) is on our radar as price action begins to signal a potential upside reversal, with the stock now setting up for a move that could challenge the $1 resistance zone if momentum continues to build. After a prolonged correction, COSM is showing early technical signs that downside pressure is fading and buyers are starting to step back in.Cosmos Health operates as a diversified pharmaceutical and healthcare company with an international footprint spanning Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus, while being headquartered in Chicago. The company manufactures and distributes prescription medications, over-the-counter drugs, nutraceuticals, medical devices, cosmetics, and wellness products across multiple established brands, including Sky Premium Life and Mediterranation.
From a market standpoint, COSM shares are down approximately 36.9% over the past 52 weeks, a decline that has pushed the stock into oversold territory and reset expectations. The recent consolidation appears constructive rather than weak, with selling pressure easing as price stabilizes.
Technically, COSM is trading within a well-defined falling wedge pattern, a structure commonly associated with bullish reversals following extended downtrends. The RSI remains near 42, suggesting the stock is no longer overbought and that downside momentum has largely been exhausted. As price continues to compress toward the upper boundary of the wedge, the probability of a breakout is increasing.
A confirmed move above the wedge resistance would open the door for a broader trend shift, placing the $2 level back into focus as a key upside area traders will be watching. This technical setup, combined with the stock’s discounted valuation and diversified healthcare exposure, is why Cosmos Health stands out as our new pick at current levels.
January 20, 2026: Press Release
Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue
Greg Siokas, CEO of Cosmos Health, stated:
"Cosmofarm continues its record-setting momentum, reflecting strong execution across customer acquisition, improving unit economics, and operational efficiency. Our ongoing investment in advanced automation significantly expands capacity and positions the platform to support incremental annual revenue potential of approximately $40 million as volumes scale. As we expand robotic infrastructure and last-mile capabilities, Cosmofarm remains a strategically important asset supporting sustainable growth and long-term value creation for Cosmos Health.”
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.